100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) + Placebo + 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperlipidemia
Conditions
Hyperlipidemia
Trial Timeline
Feb 26, 2021 → Oct 18, 2021
NCT ID
NCT04774003About 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) + Placebo + 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)
100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) + Placebo + 300 mg inclisiran sodium (equivalent to 284 mg inclisiran) is a phase 1 stage product being developed by Novartis for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04774003. Target conditions include Hyperlipidemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04774003 | Phase 1 | Completed |
Competing Products
20 competing products in Hyperlipidemia